Sign In
Buy TELA
Tela Bio Earnings Calls
| Release date | May 12, 2026 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.210 |
| EPS Surprise | -50.00% |
| Revenue estimate | 18.597M |
| Revenue actual | 19.059M |
| Revenue Surprise | 2.49% |
| Release date | Mar 25, 2026 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.160 |
| EPS Surprise | 11.11% |
| Revenue estimate | 21.034M |
| Revenue actual | 20.869M |
| Revenue Surprise | -0.785% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.190 |
| EPS Surprise | -11.76% |
| Revenue estimate | 21.041M |
| Revenue actual | 20.689M |
| Revenue Surprise | -1.67% |
| Release date | Aug 11, 2025 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.220 |
| EPS Surprise | -22.22% |
| Revenue estimate | 22.142M |
| Revenue actual | 20.197M |
| Revenue Surprise | -8.79% |
Last 4 Quarters for Tela Bio
Below you can see how TELA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 11, 2025 |
| Price on release | $1.86 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.220 |
| EPS surprise | -22.22% |
| Date | Price |
|---|---|
| Aug 05, 2025 | $1.85 |
| Aug 06, 2025 | $1.70 |
| Aug 07, 2025 | $1.67 |
| Aug 08, 2025 | $1.72 |
| Aug 11, 2025 | $1.86 |
| Aug 12, 2025 | $1.60 |
| Aug 13, 2025 | $1.47 |
| Aug 14, 2025 | $1.60 |
| Aug 15, 2025 | $1.58 |
| 4 days before | 0.541% |
| 4 days after | -15.05% |
| On release day | -13.98% |
| Change in period | -14.59% |
| Release date | Nov 13, 2025 |
| Price on release | $1.11 |
| EPS estimate | -$0.170 |
| EPS actual | -$0.190 |
| EPS surprise | -11.76% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $1.17 |
| Nov 10, 2025 | $1.19 |
| Nov 11, 2025 | $1.19 |
| Nov 12, 2025 | $1.14 |
| Nov 13, 2025 | $1.11 |
| Nov 14, 2025 | $1.00 |
| Nov 17, 2025 | $1.14 |
| Nov 18, 2025 | $1.18 |
| Nov 19, 2025 | $1.08 |
| 4 days before | -5.13% |
| 4 days after | -2.70% |
| On release day | -9.97% |
| Change in period | -7.69% |
| Release date | Mar 25, 2026 |
| Price on release | $0.690 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.160 |
| EPS surprise | 11.11% |
| Date | Price |
|---|---|
| Mar 19, 2026 | $0.750 |
| Mar 20, 2026 | $0.778 |
| Mar 23, 2026 | $0.83 |
| Mar 24, 2026 | $0.761 |
| Mar 25, 2026 | $0.690 |
| Mar 26, 2026 | $0.746 |
| Mar 27, 2026 | $0.670 |
| Mar 30, 2026 | $0.565 |
| Mar 31, 2026 | $0.620 |
| 4 days before | -7.99% |
| 4 days after | -10.16% |
| On release day | 8.11% |
| Change in period | -17.33% |
| Release date | May 12, 2026 |
| Price on release | $1.02 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.210 |
| EPS surprise | -50.00% |
| Date | Price |
|---|---|
| May 06, 2026 | $0.99 |
| May 07, 2026 | $1.10 |
| May 08, 2026 | $1.02 |
| May 11, 2026 | $0.97 |
| May 12, 2026 | $1.02 |
| May 13, 2026 | $0.96 |
| May 14, 2026 | $0.99 |
| May 15, 2026 | $0.91 |
| May 18, 2026 | $0.83 |
| 4 days before | 3.03% |
| 4 days after | -18.62% |
| On release day | -5.88% |
| Change in period | -16.15% |
Tela Bio Earnings Call Transcript Summary of Q1 2026
TELA Bio reported Q1 2026 revenue of $19.1M, up ~3% year-over-year, driven mainly by international growth (Europe +41%). OviTex unit volumes increased 16% (5,800 units) while OviTex revenue was $12.6M. The company completed a U.S. commercial rebuild and is fully staffed at its 2026 field headcount, expecting many reps to hit a 6-month productivity inflection by late Q2/early Q3. TELA launched OviTex LTR (a fully resorbable hernia portfolio) April 1 and is seeing positive early feedback. Gross margin was 66% (vs. 68% prior year); operating loss was $10.5M (flat YoY) and net loss widened to $12.3M primarily from higher interest expense related to a new credit facility. Cash was $39.5M at quarter-end. The company reiterated full-year guidance of at least 8% revenue growth over 2025 and Q2 revenue of ~ $20M, citing: (1) sales force maturation and territory densification, (2) OviTex LTR launch, (3) strong European momentum driven by NHS validation and tender dynamics, and (4) expanding clinical evidence supporting OviTex outcomes. Management emphasized the shift to deepen surgeon adoption (more users per site) to reduce concentration risk, expects the stronger second half of 2026 as hires fully ramp, and highlighted Board refresh with new directors experienced in scaling medtech.
